Add Yahoo as a preferred source to see more of our stories on Google. A file photo showing the EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company are seen in ...
Generic giant Mylan has faced a slew of lawsuits targeting its EpiPen marketing strategies. Now known as Viatris, the drugmaker says it's scored a win against serious charges in an antitrust case that ...
Viatris Inc, the drugmaker formerly known as Mylan, said on Monday it had agreed to pay $264 million to resolve a class-action lawsuit alleging it engaged in a scheme to delay generic competition to ...
As another round of EpiPen marketing litigation wraps, Mylan’s successor Viatris can chalk up another victory. Late last week, a federal court in New York tossed investors’ claims against Viatris “in ...
Viatris, a drugmaker formerly known as Mylan Pharmaceuticals, on Feb. 28 agreed to pay $264 million to settle a class-action lawsuit over EpiPen pricing, The Hill reported. At the Becker's 11th Annual ...
(Reuters) -Viatris Inc, the drugmaker formerly known as Mylan, said on Monday it had agreed to pay $264 million to resolve a class action lawsuit alleging it engaged in a scheme to delay generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results